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Effect of periodontal treatment 
in patients with periodontitis and 
diabetes: systematic review and 
meta-analysis
The evidence is inconclusive regarding the effect of periodontal treatment 
on glycemic control and systemic inflammation in patients with type 2 
diabetes (T2D) and periodontitis Objective: To evaluate the effect of scaling 
and root planing (SRP) on the metabolic control and systemic inflammation 
of patients with type 2 diabetes (T2D). Methodology: A literature search 
was conducted using the MEDLINE database via PubMed and the Cochrane 
Central Register of Controlled Trials, from their oldest records up to July 
2018. Only randomized clinical trials (RCT) were considered eligible for 
evaluating the effect of periodontal treatment on markers of metabolic control 
[glycated hemoglobin (HbA1C)] and systemic inflammation [C-reactive 
protein (CRP)] in patients with T2D. The quality of the studies was evaluated 
using the Cochrane Collaboration risk assessment tool. Meta-analyses were 
performed for HbA1c and CRP using random effects models. The size of 
the overall intervention effect was estimated by calculating the weighted 
average of the differences in means (DM) between the groups in each study. 
Heterogeneity was assessed using the Q-statistic method (x2 and I²). The level 
of significance was established at p<0.05. Results: Nine RCT were included. 
SRP was effective in reducing HbA1c [DM=0.56 (0.36-0.75); p<0.01] and 
CRP [DM=1.89 (1.70-2.08); p<0.01]. No heterogeneity was detected (I2=0%, 
p>0.05). Conclusions: SRP has an impact on metabolic control and reduction 
of systemic inflammation of patients with T2D.
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Introduction
Type 2 diabetes (T2D) and periodontitis are 
closely related noncommunicable diseases (NCDs) 
that present a high prevalence in the world, seriously 
compromising the quality of life of the affected 
population.1,2 The number of people with diabetes has 
increased from 108 million in 1980 to 422 million in 
2014 and is considerably higher in middle and lower 
income countries.3 Diabetes has become a leading 
cause of death and disability in the region of the 
Americas, and if current trends continue, the burden 
of the disease will increase substantially over the 
next two decades.4 In Mexico and in the majority of 
the countries of Central and South America and the 
Spanish-speaking Caribbean, diabetes prevalence has 
been reported between 8% and 10%.4
In Chile, according to the last National Health 
Survey,5 the prevalence of diabetes is 12.3%. In turn, 
the prevalence of periodontal destruction in Chile is 
greater than 85% in people over 35 years of age.6 
Despite the heterogeneity in the operational definition 
of the disease, most studies show that the prevalence 
of periodontitis in Latin America is high.7
Although there are no epidemiological studies of 
simultaneity of both pathologies, a meta-analysis 
showed that people with T2D have twice the risk of 
developing periodontitis compared with those without 
diabetes.8 These data show that almost all patients 
with T2D have periodontitis simultaneously.
T2D is characterized by an altered hyperglycemic 
metabolic state and is associated with a decrease 
in life expectancy of ten years and with long-term 
complications that may include cardiovascular disease, 
diabetic retinopathy, and kidney failure.9 Periodontitis, 
however, is currently considered a noncommunicable 
chronic inflammatory pathology of infectious etiology. 
The bidirectional pathogenic association between both 
diseases has been extensively documented.10 Diabetic 
patients are more susceptible to severe periodontitis 
and it may increase the risk of poor glycemic control.11 
The effect of periodontitis on diabetes may be related to 
the penetration of the host tissues by bacteria or their 
degradation products into the systemic circulation. 
Activation of an exaggerated systemic inflammatory 
response to subgingival bacteria leads to an acute 
phase protein burst and systemically elevated levels 
of proinflammatory mediators which facilitate insulin 
resistance.12,13 Metabolic dysregulation in diabetes as a 
result of prolonged exposure to chronic hyperglycemia 
can lead to the glycosylation of proteins and lipids, 
called advanced glycation end- products (AGEs). They 
can explain many of the sequelae of diabetes, such as 
microvascular complications. Local periodontal tissue 
destruction may be a consequence of an exaggerated 
monocytic inflammatory response induced by AGEs 
accumulation and result in exaggerated secretion 
of local and systemic mediators leading to severe 
periodontitis.14 The binding of AGEs to monocyte 
receptors induces production of interleukin- 1 (IL-1), 
IL-6, insulin- like growth factor-1, tumor necrosis 
factor- alfa (TNF-a) and platelet- derived growth 
factor.15 Those are some factors that initiate and 
maintain an inflammatory response and regulate 
the transcription of human Acute Phase Reactants, 
like C-reactive protein (CRP). CRP is a sensitive 
inflammatory marker and an independent predictor 
of cardiovascular diseases.16
The poor glycemic control of diabetic patients, 
defined as glycated hemoglobin (HbA1c) values >7%, 
is associated with microvascular and macrovascular 
complications.17 Macrovascular complications also 
known as cardiovascular diseases (CVD) are an 
important cause of morbidity and mortality among 
individuals with T2D. Patients with T2D have an 
increased risk of premature atherosclerotic plaque 
development, which is the central pathogenic 
mechanism of CVD. To a great extent, the endothelial 
dysfunction present in patients with poor glycemic 
control is associated with the high production of CRP 
as a result of systemic inflammation caused by AGEs.18 
The role of systemic inflammation and, consequently, 
of high levels of CRP has been described in all phases 
of atherosclerosis, from the onset and build-up of 
plaque to rupture. From the biological point of view, 
CRP participates in the atherogenic process, and its 
concentration predicts cardiovascular events.19 The 
cardiovascular effects of CRP have been described 
mainly through endothelial dysfunction by reducing 
nitric oxide levels. Endothelial dysfunction facilitates 
the activation, migration, and lodging of leukocytes 
inside the tunica intima. This phenomenon contributes 
to the formation of vascular lesions that are the basis 
of the development of atherosclerosis. When low-
density lipoproteins reach a certain concentration 
threshold in the blood, they penetrate the interior of 
the arterial wall, where they are modified by oxidation 
processes. CRP binds to these lipoproteins (both 
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native and oxidized) and facilitates phagocytosis 
and internalization mediated by the macrophages 
of the intima, promoting the formation of foam cells 
(macrophages with large amounts of oxidized lipids 
inside). The accumulation of foam cells is determinant 
for the pathogenic evolution of an arterial plaque, 
making it more prone to erosion or rupture and 
releasing its thrombogenic content. This prothrombotic 
property also adds to the ability of CRP to induce the 
production of tissue factor (initiator of the coagulation 
cascade) by activated macrophages.20 Also, CRP levels 
are elevated in patients with periodontitis21.22 and their 
CRP levels may go down after periodontal therapy.21
Studies conducted in the last decade indicate that 
the control of chronic inflammatory processes caused 
by periodontitis may constitute a new approach in 
reducing the risk of cardiovascular complications in 
patients with T2D. Based on this concept, clinical 
trials have been designed to determine the possible 
beneficial effects of conventional periodontal treatment, 
consisting of the mechanical removal of the subgingival 
biofilm by means of scaling and root planing (SRP) in 
diabetic patients. Despite the variability, the results of 
these studies have been mostly favorable. However, 
systematic reviews have been limited to the analysis of 
HbA1c as an end point measure,23 without considering 
other variables such as those associated with systemic 
inflammation that can provide us with a better approach 
to reducing the risk of diabetic complications, especially 
those related to CVD. The objective of this systematic 
review was to answer the following question: Can 
conventional periodontal treatment compared with the 
absence of periodontal treatment improve metabolic 
control and reduce systemic inflammation in patients 
with periodontitis and T2D?
Methodology
Protocol
The protocol was designed in accordance with the 
Cochrane standards for systematic reviews. The search 
criteria complied with the Preferred Reporting Items 
for Systematic reviews and Meta-Analysis Protocols 
(PRISMA) guidelines.
Criteria for the inclusion of studies
Type of studies: The study design was a randomized 
controlled clinical trial, as it is the most appropriate 
type of study to answer the research question since 
it presents a lower risk of systematic errors and 
greater control over potential confounding variables, 
constituting the best scientific evidence to support the 
efficacy of therapeutic interventions.
Type of participants and inclusion/exclusion criteria: 
Participants with a diagnosis of T2D and periodontitis 
were included. Other inclusion criteria were the 
following: (1) Participants with 3 or more months of 
post intervention follow-up and (2) HbA1c and CRP 
evaluation at the beginning and end of the follow-up.
Types of periodontal interventions: Periodontal 
interventions were based on different conventional 
treatments, including oral hygiene instruction and SRP 
(with or without flap surgery). Periodontal interventions 
were compared with the passive option (without 
periodontal treatment).
Outcomes:
Primary: HbA1C and CRP
Secondary: Occurrence of adverse events related 
to periodontal treatment.
Search strategy
We searched the following databases from their 
oldest records until July 10, 2018: 1) MEDLINE through 
PubMed and 2) Cochrane Central Register of Controlled 
Trials (CENTRAL). The articles in both databases are 
only available in English. The search terms (MeSH 
terms) were ‘‘periodontitis’’ OR ‘‘periodontal” AND 
(therapy OR treatment) AND (diabetes OR metabolic 
control OR glycemic control OR glycated hemoglobin 
OR HbA1c OR systemic inflammation OR C-reactive 
protein OR hsCRP). 
Study eligibility and data extraction
All retrieved articles were evaluated by two 
independent reviewers (MB and AM). Inter reviewer 
reliability in the study selection process was determined 
by the Cohen k test, assuming an acceptable threshold 
value of 0.61.24,25 Disagreements were resolved by 
consensus. If a disagreement persisted, the judgment 
of a third reviewer (JG) was considered final. Irrelevant 
records (abstracts not available, bibliographic reviews, 
descriptive studies, animal studies) were excluded, 
and the full texts of potentially relevant studies 
were examined to answer the question of interest. 
The relevant studies that met the inclusion criteria 
were analyzed, with the following data extracted: 
1) demographic characteristics (age, sample size, 
country where the study was conducted), 2) definition 
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of disease, 3) control measures of T2D, 4) periodontal 
intervention, 5) outcome variable (HbA1c and/or CRP) 
and their initial values, 6) follow-up period and final 
values, and 7) results (average change in HBA1c and/
or CRP in each group).
Quality of the evidence
The evaluation of the quality of the selected studies 
was carried out using the Cochrane Collaboration tool 
to assess the risk of bias.26
Diagnostic evaluation
T2D was diagnosed according to the criteria of the 
World Health Organization,27 defined as fasting plasma 
glucose >126 mg/dl and/or impaired oral glucose 
tolerance test at 2 h. Due to the heterogeneity of 
the criteria and the definitions of periodontitis, any 
diagnosis of periodontitis was accepted as defined by 
the authors.
Statistical analysis
The data extracted from the studies were analyzed 
using RevMan 5.3 software (The Nordic Cochrane 
Centre, The Cochrane Collaboration, Copenhagen, 
Denmark). The corresponding meta-analyses were 
carried out to determine the effect of the periodontal 
intervention on the variables HbA1c and CRP, 
comparing the group that received the periodontal 
treatment (intervention group) with the group that did 
not receive periodontal treatment (control group). The 
effect size was estimated and reported as the difference 
between the intervention group and the control group 
in the means of the changes occurring in the levels of 
HbA1c and CRP between the start and the end of the 
follow-up, and the 95% confidence interval (CI) was 
calculated. Due to the expected heterogeneity between 
the studies, a random effects model was used.28 The 
combined overall effect (weighted average) was 
considered significant if p<0.05. The forest plots for 
each meta-analysis present raw data (means, standard 
deviations, and sample sizes), point estimates (shown 
as blocks) and CIs (shown as lines) of the effect of each 
study, the total number of participants per group, the 
general average effect of the model (Z statistic), and 
the weight percentage for each study. Heterogeneity 
was assessed using the Q-statistic method based on 
x2 and the I2 measurement. The publication bias of the 
articles was investigated for each outcome variable 
(HbA1c and CRP) by visual inspection of asymmetries 
in the funnel plot.29
Results
Search results
A total of 402 articles were retrieved using 
databases from two online sources (MEDLINE and 
Cochrane Library). After the elimination of duplicates 
(n=53), 349 titles and abstracts were reviewed, 292 
of which were excluded because they did not meet the 
basic inclusion criteria (designs without intervention, 
reviews, or patients with DT1) (inter- reviewer 
agreement, k=0.76). Fifty-seven complete articles 
were evaluated in more detail to determine their 
eligibility, nine of which met the criteria for inclusion 
in the systematic review and meta-analysis (inter 
reviewer agreement, k=0.88). The flow chart following 
the PRISMA criteria and model of the complete search 
and inclusion process of the studies is illustrated in 
Figure 1.
Description of the studies
The main characteristics of the included studies 
(n=9) are presented in Figure 2. All the included 
studies30-37 were randomized clinical trials with a 
control group without periodontal intervention. To 
control for the possible placebo effect, oral hygiene 
instruction (IHO) was administered in two studies;31-36 
supragingival scaling was performed in another study 
in the control group;34 and no type of treatment was 
reported for the control group in the remaining studies. 
The intervention in all the studies was a conventional 
periodontal treatment with nonsurgical (SRP), except 
for the study by Chen, et al.30 (2012), which included 
surgical debridement at 3 months. The definition used 
for the diagnosis of periodontitis varied widely among 
the studies. Periodontitis was diagnosed in four studies 
according to the criteria of the American Academy of 
Periodontology (AAP),30,34,35,37 in one study36 according 
to the Eke criteria,38 in another study according to 
unspecified criteria,33 and in the remaining three 
studies according to different severity criteria.32,37,39 
Regarding smoking, one study excluded smokers,37 
another did not report whether smokers were included 
as a selection criterion,39 and the rest of the studies 
included smokers, with a balance between the groups 
after randomization. In relation to T2D, all the studies 
reported the diagnostic criteria following the WHO 
guidelines, with a variable onset date. In turn, all 
reported metabolic control measures for the treatment 
of T2D, except one,39 and all reported that there were 
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no changes in the T2D treatment scheme during 
follow-up, except one that did not report these data.35 
The initial values, final values, and changes (delta) in 
HbA1c and/or CRP in each group of each study are 
presented in Figure 1.
The main reasons to exclude 49 studies were 
“inadequate control group” (n=25),40-64 “inadequate 
intervention and/ or inadequate case definition” 
(n=17),65-81 “inadequate evaluation and or high risk 
of bias” (n=6)82-87 (Figure 7).
Risk of bias in the included studies
To determine the validity of the included studies, 
a tool developed by the Cochrane Collaboration was 
used to assess the risk of bias in clinical trials.26 
Using this tool, the reviewer evaluated the risk 
of bias of the selected studies using the following 
parameters: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
analysis intention (blinding of outcome assessment), 
incomplete outcome data, selective reporting (selection 
of the reported results), and other types of bias not 
considered previously (e.g., design bias, contamination 
bias). All articles adequately reported random sequence 
generation, allocation concealment, blinding of outcome 
assessment, incomplete outcome data and selective 
reporting. In six articles in which the control group 
did not undergo any procedure, it was not possible to 
blind the personnel and the participants; only in one 
study34 was it possible to ensure the blinding of the 
participants, and blinding in the other two studies was 
unclear.31,69 Other unspecified types of bias were also 
considered as associated with the lack of information 
regarding control measures and possible changes in 
the management of T2D39 or interventions performed 
by a general dentist and nonspecialist,36 and there 
were less clear situations such as those related to 
the contamination of the results (contamination bias) 
due to the effect of procedures in the control group 
(debridement and/or IHO). The general scheme of the 
risk of bias is presented in Figure 3, and a detailed 
summary by study is provided in Figure 4.
Effect of the intervention
Primary HbA1c Outcomes: The results of the meta-
analysis indicate a significant reduction in %HbA1c 
from the beginning to the end of the follow-up in the 
intervention group [differences in means (DM)=0.56, 
Figure 2- Selection of studies for systematic review
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95% CI (0.36-0.75), p<0.00001]. In this meta-
analysis, no heterogeneity was detected among the 
included studies (x2=5.89, I2=0%, p=0.66) (Figure 
6A).
Primary CRP Outcomes: Regarding the results of 
CRP levels, the meta-analysis indicated a significant 
reduction from the start to the end of follow-up in favor 
of the intervention group [DM=1.89, 95% CI (1.70-
2.08), p<0.00001]. No heterogeneity was detected 
among the included studies (x2=0.36, I2=0%, p=0.83) 
in this meta-analysis (Figure 6B).
Secondary Outcome: None of the included 
studies reported the occurrence of adverse effects or 
complications related to periodontal treatment.
Publication biases
Visual inspection of the funnel plot for studies 
included in the meta-analysis that evaluated the effect 
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Figure 2- Characteristics of studies included in the systematic review
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of periodontal treatment on HbA1c levels does not 
suggest the presence of publication biases (Figure 
7). Regarding the studies included in the CRP meta-
analysis, the limited study number does not allow a 
clear assessment of the absence of possible publication 
bias.
Inadequate control group (n=25) Inadequate intervention and/or 
inadequate case definition (n=17)
Inadequate evaluation and/or high risks 
of bias (n=6)
Grossi, et al.48 (1997) Khader, et al.72 (2010) Li, et al.84 (2009)
Rodrigues, et al.57 (2003) Calabrese, et al.65 (2011) Zhang, et al.87 (2013)
Skaleric, et al.60 (2004) Nassar, et al.74 (2011) Hincapié, et al.83 (2014)
Yun, et al.63 (2007) Obradović, et al.75 (2011) Raman, et al.86(2014)
O’Connell, et al.54 (2008) Cirano, et al.66 (2012) Bezerra, et al.82 (2015)
Llambes, et al.51 (2008) Kapellas, et al.71 (2013) Priyanka, et al.85 (2015)
Santos, et al.58 (2009) Santos, et al.79 (2013)
Al-Zahrani, et al.41 (2009) Wehmeyer, et al.81 (2013)
Engebretson and Hey-Hadavi46 (2011) Nassar, et al.74 (2014)
Gilowski, et al.47 (2012) Saengtipbovorn, et al.78 (2014)
Santos, et al.59 (2012) Cullinan, et al.68 (2015)
Pradeep, et al.56 (2013) Jamieson, et al.70 (2015)
Macedo, et al.52 (2014) Gelato, et al.69 (2016)
Miranda, et al.53 (2014) Ramos, et al.76 (2016)
Tsalikis, et al.62 (2014) Cortelli, et al.67 (2017)
Castro Dos Santos, et al.43 (2016) Sabatini, et al.77 (2017)
El-Sharkawy, et al.45 (2016) Tsobgny-Tsague, et al.80 (2018)
Kumari, et al.49 (2016)
Pradeep, et al.55 (2016)
Tamashiro, et al.61 (2016)
Al-Askar, et al.40 (2017)
Demirturk-Gocgun, et al.44 (2017)
Lira Junior, et al.50 (2017)
Barbosa, et al.42 (2018)
Zare Javid, et al.64 (2018)
Figure 3- Characteristics and names of the excluded studies (n=49)
Figure 4- Risk of bias graph: review author’s judgment about each risk of bias item presented as percentages across all included studies
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Discussion
The present systematic review with its two meta-
analyses indicates that conventional periodontal 
treatment can improve metabolic control and reduce 
systemic inflammation in patients with T2D by reducing 
serum levels of HbA1c and CRP, respectively. The results 
of the metabolic control achieved by treatment and the 
reduction of systemic inflammation are consistent with 
the results of other systematic reviews and meta-
analyses.88-90 However, in the present review, for the 
first time, the effect of the periodontal intervention on 
both outcome variables was evaluated simultaneously, 
with the same study methodology and inclusion criteria. 
Thus, this review used strict eligibility criteria, such as 
the presence of ≥3 months of follow-up, which reflects 
the period in which the changes in HbA1c and CRP are 
more stable and relevant. In addition, randomized 
studies comparable to each other were included, which 
strongly contributed to the reliability of the results.
The meta-analysis determining the overall effect of 
periodontal treatment on HbA1c levels showed relative 
consistency between the studies included, an absence 
of heterogeneity (I2=0%), and a significant effect in 
the intervention group (p<0.01). These results, similar 
to those previously found, reinforce the hypothesis 
that suggests that periodontal treatment generates 
improved HbA1c levels in patients with T2D. The effect 
size, measured in terms of mean differences between 
the delta (initial-final) of the intervention group vs. 
control, showed an overall effect of 0.56% (0.36-
0.75) at the end of the follow-up period. The clinical 
implications of achieving better metabolic control of 
diabetic patients are clearly established; specifically, 
the microvascular complications related to diabetes 
are reduced by 35% for each 1% decrease in HbA1c 
levels. Additionally, an absolute decrease of 1% in the 
HbA1c level can decrease the risk of any death related 
to diabetes by 21%.17 Future studies are necessary to 
determine the direct impact of periodontal treatment on 
complications and the risk of dying associated with T2D.
Although these results (0.56%) are consistent 
with previous studies, it is interesting to see that 
the overall effect found in this study considerably 
exceeds the 0.29% HbA1c reported by Simpson, et 
al.89 (2015). It is likely that the incorporation of studies 
subsequent to Simpson’s review, such as the study 
by Kaur, et al.32 (2015), will favor the results of the 
present study. Another major explanation is that in the 
studies included in the present review the interventions 
were based on conventional periodontal treatment 
that included: oral hygiene instruction and SRP (with 
or without flap surgery) compared with the passive 
option (without periodontal treatment), these results 
were similar to those reported by Simpson, et al.89 
(2015) with a reduction of 0.41% HbA1c when similar 
conditions were analyzed. However, when Simpson 
analyzed different interventions, for example, when 
incorporating antimicrobials or alternative periodontal 
treatments, the results were considerably lower89.
Regarding CRP levels, although the meta-analysis 
showed a significant overall effect with an absence 
of heterogeneity, this result must be evaluated with 
caution due to the small number of studies analyzed. 
However, the results are consistent with each other 
and with other studies88 that reflect the impact of 
Figure 5- Risk of bias summary: review author’s judgments about 
each risk of bias item for each included study
Effect of periodontal treatment in patients with periodontitis and diabetes: systematic review and meta-analysis
J Appl Oral Sci. 2020;28:e201902489/13
periodontal treatment at the marker-level of systemic 
inflammation. This result complements those found in 
previous systematic reviews in relation to the potential 
effects of periodontal treatment on the general health 
of patients with T2D, enhancing the hypothesis 
regarding a dual explanatory path for reducing 
systemic inflammation, namely, one path directly 
through the reduction of proinflammatory mediators 
such as TNF-alpha, IL-1, and IL-6, which induce acute-
phase responses with hepatic biosynthesis and elevated 
serum CRP levels, and another path indirectly through 
the reduction of HbA1c itself as a result of the reduction 
of insulin resistance. In this case, the effect size was a 
mean difference of 1.89 mg/l [(1.70-2.08), p<0.01]. 
CRP is the most commonly used inflammatory marker 
in clinical practice, and its importance not only lies in 
its reliability but also, along with some other acute-
phase reactants, in its ability to be an active part of the 
pathogenic mechanism of atherosclerosis.91 Prospective 
studies show that increased CRP plasma concentrations 
of small magnitude, even within limits that were 
previously considered “normal” (below 10 mg/L), 
predict acute cardiovascular events apart from other 
risk factors.92 Patients with T2D present an increase 
in systemic inflammation, which partly explains the 
considerable increase in cardiovascular risk. This 
increase in inflammation adds to the presence of 
chronic inflammatory processes such as periodontitis, 
which constitutes an additional source of systemic 
proinflammatory mediators, and could explain the even 
greater increase in cardiovascular risk.
The included studies considered different levels 
of severity and extent of periodontitis (moderate, 
moderate to advanced, severe) that could have an 
impact on the final outcome (systemic and local). More 
severe pathologies could generate a more significant 
change in the local and systemic inflammation of 
patients with T2D, which could partly explain some 
differences in the results. Similarly, the included 
studies presented differences in their criteria for 
selecting diabetic patients with different degrees of 
metabolic control. Increased changes in HbA1c levels 
after periodontal treatment have been observed in 
patients with poor metabolic control and/or patients 
with acceptable or optimal control of HbA1c levels 
(<7%).32 When stratifying by level of control, it was 
observed that the deltas (initial-final) in the periodontal 
intervention group were 1.49±0.98% in patients with 
poor control (HbA1c<7%) and 0.16±0.32% in patients 
with good metabolic control. Quintero, et al.93 (2018) 
Figure 6- Forest Plot of comparision: A. Periodontal therapy outcome: Change in HbA1c (%HbA1c). B. Periodontal therapy outcome: 
Change in CRP
Figure 7- Funnel plot of comparision: Periodontal therapy 
outcome: Change in HbA1c
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reported that periodontal treatment generated a 
greater impact in the reduction of HbA1c in patients 
with levels >9% (0.31% vs 0.88%).93 These aspects 
must be considered for future research and for an 
adequate interpretation of the results.
Regarding the excluded studies, 272 studies were 
excluded in a first phase of screening. Since this phase, 
differences have already been observed with Simpson’s 
Cochrane review,89 which unlike ours includes patients 
with type 1 diabetes. Later in the eligibility stage, 48 
complete articles were excluded due to inadequate 
control group (n=25), inadequate intervention and/
or inadequate case definition (n=17) and inadequate 
evaluation and/or high risks of bias (n=6). There are 
clearly differences with the Simpson’s review who uses 
different modalities of periodontal treatment (with the 
use of antimicrobials or new therapies) not included 
in the present review. Other articles such as Zhang, 
et al.87 (2013) or Li, et al.84 (2011) for presenting an 
inadequate evaluation and high risks of bias were also 
excluded from the present review. This may explain 
why the Simpson’s Cochrane review includes more 
articles (n=35) and excludes less (n=12) unlike our 
review that includes less (n=9), and excludes more 
(n=49). Our purpose was to be highly rigorous when 
including the studies for the present systematic review. 
More details of the characteristics and names of the 
excluded studies are presented in Figure 3.
The quality of evidence from a systematic review 
depends to a large extent on the quality of the included 
studies. In this case, the eligible study design was 
the randomized controlled clinical trial that, due to its 
lower risk of bias, represents the most appropriate 
design for assessing the efficacy of periodontal 
treatment. However, it is necessary to clarify that the 
type of study does not necessarily guarantee a good 
quality of evidence and that, therefore, clinical trials 
may also present biases that prevent the attainment 
of accurate results, invalidating our results. In this 
case, the included studies presented some risks of 
important biases that included performance bias due 
to the inherent nature of the design and the lack of 
an adequate placebo. Regarding other sources of bias, 
generally, the included studies are of good quality 
because they have low risks of systematic errors.
Another limitation of this study was the lack of 
a statistical analysis to evaluate the possibility of 
publication bias (such as the Egger test) that could 
support the funnel plot results. In addition, it should 
be noted that only two database sources were used for 
the bibliographic search; since other databases exist, 
it is important for future reviews to include additional 
sources of information. Finally, only English language 
literature was reviewed. Searching vernacular indexed 
literature might give more data for systematic review.
The high prevalence, morbidity and mortality of 
T2D explain why the management of the disease and 
its complications consume such a high percentage 
of the health budget of different countries. While in 
Chile it reaches 10.2%,94 in Mexico it exceeds 15% 
of the total health budget. In 2014, DM2 caused 4.9 
million deaths and an expenditure of 612 billion dollars 
worldwide.95
The results of the present systematic review with 
its two meta-analyses reinforce and complement 
the evidence regarding the efficacy of periodontal 
treatment in the improvement of metabolic control 
and in the reduction of systemic inflammation of 
patients with T2D. In this context, the implication of 
incorporating periodontal treatment into the care of 
patients with T2D could constitute a policy of high 
impact for the public health of the country.
Conclusion
SRP has an impact on metabolic control and 
reduction of systemic inflammation of patients with 
T2D. Periodontal treatment could constitute an 
innovative therapeutic approach as a public health 
measure to reduce complications and improve 
the cardiovascular health of patients with T2D. 
Intervention and cost-effectiveness studies in the 
context of public health systems in different countries 
are necessary to evaluate the possible design of public 
policies in this area.
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